The structurally related T cell surface molecules CD28 and CTLA-4 interact with cell surface ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APC) and modulate T cell antigen recognition. Preliminary reports have suggested that CD80 binds CTLA-4 and CD28 with affinities (Kd values ∼12 and ∼200 nM, respectively) that are high when compared with other molecular interactions that contribute to T cell–APC recognition. In the present study, we use surface plasmon resonance to measure the affinity and kinetics of CD80 binding to CD28 and CTLA-4. At 37°C, soluble recombinant CD80 bound to CTLA-4 and CD28 with Kd values of 0.42 and 4 μM, respectively. Kinetic analysis indicated that these low affinities were the result of very fast dissociation rate constants (koff); sCD80 dissociated from CD28 and CTLA-4 with koff values of ⩾1.6 and ⩾0.43 s−1, respectively. Such rapid binding kinetics have also been reported for the T cell adhesion molecule CD2 and may be necessary to accommodate dynamic T cell–APC contacts and to facilitate scanning of APC for antigen.
Skip Nav Destination
Article navigation
3 February 1997
Article|
February 03 1997
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
P. Anton van der Merwe,
P. Anton van der Merwe
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Search for other works by this author on:
Dale L. Bodian,
Dale L. Bodian
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Search for other works by this author on:
Susan Daenke,
Susan Daenke
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Search for other works by this author on:
Peter Linsley,
Peter Linsley
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Search for other works by this author on:
Simon J. Davis
Simon J. Davis
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Search for other works by this author on:
P. Anton van der Merwe
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Dale L. Bodian
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Susan Daenke
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Peter Linsley
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Simon J. Davis
From the *Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; ‡Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, United Kingdom; §Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‖Molecular Sciences Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Address correspondence to P. Anton van der Merwe, MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom.
We gratefully acknowledge Neil Barclay, Marion Brown, and Don Mason for providing valuable advice and critically reading this manuscript; Liz Davies for constructing the sCD80his-encoding plasmid; Marion Brown and Fabiana Horn for expression and purification of CTLA-4 Ig; and Tony Willis for performing the amino acid analyses. We thank Drs. D. Olive, R.A.W. van Lier, and K. Sagawa for kindly providing us with monoclonal antibodies listed in Table 1.
This work was supported by the United Kingdom Medical Research Council and the Wellcome Trust. D.L. Bodian was supported by the Cancer Research Fund of the Damon Runyon–Walter Winchell Foundation, Fellowship DRG-1246.
1Abbreviations used in this paper: CHO, Chinese hamster ovary; FC, flow cell; koff, dissociation rate constant; kon, association rate constant; RU, response unit; sCD80his, soluble CD80 with carboxy-terminal oligo-histidine tag; SPR, surface plasmon resonance.
Received:
August 14 1996
Revision Received:
November 07 1996
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1997
J Exp Med (1997) 185 (3): 393–404.
Article history
Received:
August 14 1996
Revision Received:
November 07 1996
Citation
P. Anton van der Merwe, Dale L. Bodian, Susan Daenke, Peter Linsley, Simon J. Davis; CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics. J Exp Med 3 February 1997; 185 (3): 393–404. doi: https://doi.org/10.1084/jem.185.3.393
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
